Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
08 Apr 2026 bởiAudrey Abella

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
08 Apr 2026
CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
27 Mar 2026 bởiKanas Chan

In an observational study of two community-based cohorts in Hong Kong, 6.7 percent of individuals with BMI ≥25 kg/m2 were reclassified as nonobese after applying the Lancet Commission’s definition of obesity. Individuals with clinical obesity had the highest risk of adverse cardiovascular-kidney-metabolic (CKM) outcomes, while those reclassified as nonobese had an intermediate risk. 

CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
27 Mar 2026